Summary

21
The emergence of HBV drug-resistant (and multidrug-resistant) strains during long-term therapy 22 with nucleos(t)ides analogs is associated with treatment failure and represents therefore a clinical telbivudine (LdT) and tenofovir (TDF), has resulted in a significant reduction in patient morbidity 10 and mortality. Yet the efficacy of treatments for CHB can be affected by a number of factors, makeup of host and immune system are also important to explain the emergence of a particular 27 strain, but this will not be further developed here as this review focuses on virus related parameters.
28
The therapeutic pressure represents also an important environmental parameter to explain the 
33
The virologic parameters of HBV fitness are the capacity of a strain to synthesize its genome, to of the virus are necessary to properly measure the fitness of a viral strain. For HBV such models do 1 no exist. Therefore to get insight into HBV fitness, several more or less artificial assays that will be 2 hereafter named replication, assembly and infectivity assays have been developed. to 2 HBV genome units into hepatoma cell lines (e.g. Huh7 or HepG2).
13
The vector-free method relies on an original and efficient PCR amplification of full-length HBV intracellular DNA due to the rather low sensibility of the methodology.
17
Beside the molecular approach used, the choice of the cell line for the transfection is also important 18 as differences in term of replication capacity and drug susceptibility have been observed [9, 24] .
19
Altogether an important effort to standardize assays intra and inter laboratory remains to be made in
20
order to move from current data that are mainly valid in a relative context (i.e. comparison with the 21 same approach in the same laboratory) to fully comparable data.
22
It is worth noting that another approach to characterize viral drug resistance in tissue culture is the 
39
Beside their impact on viral assembly, mutations may also impact the antigenicity and therefore the 40 ability of a strain to be neutralised by circulating or administrated antibodies [29, 30] . comparative infectivity analysis, the critical issue is to standardize the inoculum to be used. with HBV or HDV particles, the intensity of infection is measured by either Northern blot or qRT-
13
PCR to detect HBV or HDV RNAs. There are differences between HBV and HDV based models.
14 With HDV, there is a disconnection between entry and replication, as the latter occurs irrespective indicates that this strain is fitter than others in this particular microenvironment. Villet et al. 25 managed to obtain in vitro data on the viral fitness of a multi-resistant strain that emerged after 26 treatment with lamivudine, adefovir, and anti-HBV immunoglobulins [7] . The in vitro data 27 confirmed that the finally selected strain was the fittest one amongst the four strains that were yet 
